SecBot SecBot
8-K ·Filed Sep 14, 2026

IMCR

Immunocore Holdings plc
BULLISH
Impact 6/10
Horizonmonths Processed2mo ago SEC0001671927-26-000026
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

The enrollment milestone removes a key timeline risk for the TEBE-AM readout. Monitor for topline OS data expected by end of 2026, a positive result could significantly expand KIMMTRAK's addressable market beyond uveal melanoma into the larger cutaneous melanoma setting.

DirectionBullish
Confidencehigh
Horizonmonths

KIMMTRAK

▲ Bullish Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercialized (since January 2022). Label expansion into cutaneous melanoma depends on Phase 3 TEBE-AM data expected by end of 2026; if positive, an sBLA submission would follow, with potential approval in 2027-2028.
Next catalyst
None dated

What to watchThe key near-term catalyst is the Phase 3 TEBE-AM topline readout for KIMMTRAK in cutaneous melanoma, expected by end of 2026 (~4 months away). A positive result could double the addressable market; a negative readout would be a major setback. With ~16.4% of shares short and ~18.8 days to cover, a positive readout could trigger significant short-covering upside. Watch for enrollment completion announcements and any data updates at medical meetings in H2 2026.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$32.46
T+0 close · Sep 14, 2026 · via day close
Latest settled
−10.54%
T+20 · $29.04 · next T+60 in 21d
Vs SPY
−12.80%
α at T+20
Latest observation
−4.92%
T+44 · FF3 residual α
  1. T+0 · Sep 14 $32.46entry
  2. T+1 · 2mo ago −2.11%α −1.65% · $31.78
  3. T+5 · 8w ago −0.86%α −0.97% · $32.18
  4. T+20 · 5w ago −10.54%α −12.80% · $29.04
  5. T+45 · todayOpen
  6. T+60 · in 21d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immunocore announced it has achieved target enrollment of 540 patients in its Phase 3 TEBE-AM registrational trial evaluating tebentafusp (KIMMTRAK) in previously treated advanced melanoma. Topline overall survival data is expected as early as end of 2026. This is a positive clinical milestone that de-risks the trial timeline but provides no efficacy data yet.

Key Facts

  • Target enrollment of 540 patients achieved in Phase 3 TEBE-AM trial of tebentafusp in previously treated advanced melanoma
  • Topline overall survival data expected as early as end of 2026
  • Trial evaluates tebentafusp as monotherapy and in combination with pembrolizumab vs investigator's choice
  • Primary endpoint is overall survival
  • Company estimates up to 4,000 HLA-A*02:01-positive patients in the US and Europe with this indication

Financial Impact

No financial data in filing; clinical milestone de-risks a potential label expansion opportunity for KIMMTRAK into a larger melanoma market (cutaneous vs current uveal melanoma indication)

Risk Factors

  • No efficacy data yet, OS results may fail to meet statistical significance
  • Competition from existing PD-1 and BRAF-targeted therapies in post-PD1 advanced melanoma
  • KIMMTRAK carries a boxed warning for Cytokine Release Syndrome which may limit adoption

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
77% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001671927-26-000026
Document: pressrelease-tebexamenroll.htm0001671927-26-000026
Document: 0001671927-26-000026-index-headers.html0001671927-26-000026
Document: 0001671927-26-000026-index.html0001671927-26-000026
Document: 0001671927-26-000026.txt0001671927-26-000026

Track record

14 reports on IMCR

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +28.39% at T+60 after the May 31, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 9, 20267d ago SC 13G Neutral 4/10 Entry $32.38 Now $28.88 −10.81% settles Feb 8
  2. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $30.99 Now $28.88 −6.81% settles Feb 4
  3. Nov 6, 202610d ago 8-K Neutral 4/10 No price data
  4. Nov 6, 202610d ago Press Release Bearish 5/10 Entry $30.99 Now $28.88 +6.81% settles Feb 4
  5. Oct 29, 202618d ago Press Release Neutral 3/10 Entry $31.27 Now $28.88 −7.64% settles Jan 27
  6. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $29.48 Now $28.88 −2.04% settles Jan 12
  7. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $29.41 Now $28.88 −1.80% settles Jan 4
  8. Sep 14, 20269w ago 8-K Bullish 6/10 Viewing Entry $32.46 Now $28.88 −11.03% settles Dec 8
  9. Aug 6, 202614w ago 8-K Mixed 5/10 Entry $34.50 to $30.49 Now $28.88 −16.29% ▼ −11.62% −9.95% vs SPY
  10. May 31, 202624w ago Press Release Bullish 6/10 Entry $29.13 to $37.40 Now $28.88 −0.86% ▲ +28.39% +27.16% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens Wed (10h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026